Hcyb1

Hcyb1 is a highly selective, orally active PDE2 inhibitor. Hcyb1 has a highly selective inhibition of PDE2A (IC50=0.57 μM) and over 250-fold selectivity against other recombinant PDE family members. Hcyb1 produces neuroprotective and antidepressant‐like effects most likely mediated by cAMP/cGMP-CREB-BDNF signaling[1].

Product Specifications

CAS Number

[2988566-71-6]

UNSPSC

12352005

Target

Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/hcyb1.html

Purity

98.20

Solubility

DMSO : 62.5 mg/mL (ultrasonic)

Smiles

O=C1NC(CC2=CC=CC=C2)=NC3=C1N=CN3C(C)C4=C5C=CC=CC5=CC=C4

Molecular Formula

C24H20N4O

Molecular Weight

380.44

References & Citations

[1]Li Liu, et al. The neuroprotective and antidepressant-like effects of Hcyb1, a novel selective PDE2 inhibitor. CNS Neurosci Ther. 2018 Jul;24 (7) :652-660.|[2]Meng-Jia Zhu, et al. Phosphodiesterase 2 inhibitor Hcyb1 reverses corticosterone-induced neurotoxicity and depression-like behavior. Psychopharmacology (Berl) . 2020 Nov;237 (11) :3215-3224.